Pfizer Stock News

Covid jabs for children of five and over is welcome news for most families – although anxieties linger Coronavirus – latest updates See all our coronavirus coverage Children aged five to 11 in England , Wales and Scotland will be offered protection against Covid, meaning millions more will be eligible for the Pfizer/BioNTech vaccine. The Pfizer vaccine, given at one-third the dose of adults, was approved as safe and effective for children by the UK’s Medicines and Healthcare products Regulatory Agency in December. But the Joint Committee on Vaccination and Immunisation previously recommended the vaccine only for vulnerable five- to 11-year-olds. Continue reading…

LONDON: All children aged five to 11 in England will be offered a Covid-19 vaccine, the UK government said Wednesday, following similar announcements in the rest of the UK. The move, coming nearly two months after British regulators approved Pfizer and BioNTech''s shot for use among the age group, sees Britain following the lead of the United States, the European Union and other countries. It has only been vaccinating at-risk under-12s and those who live with immuno-suppressed people, using a lower-dose formulation of the jab that was found to be "safe and effective". However, Health Secretary Sajid Javid -- who has responsibility for England only -- said he had now accepted guidance from the Joint Committee on Vaccination and Immunisation, which advises UK health departments, to expand the rollout. "The NHS (National Health Service) will prepare to extend this non-urgent offer to all children during April so parents can, if they want, take up the offer to increase protection against potential future waves of Covid-19 as we learn to live with this virus," he said in a statement.

The tech-focused hedge fund has large positions in electric vehicle and vaccine stocks, securities filings show.

All children aged five to 11 years in the U.K. will be offered Pfizer (PFE)/BIonTech (BNTX) COVID-19 vaccine from April, the government confirmed on Wednesday

German vaccine maker BioNTech, which developed the first widely approved shot against Covid-19 together with Pfizer, unveiled plans on Wednesday to establish manufacturing facilities in Africa that would boost the availability of much-needed medicines on the continent.The modular design presented at a ceremony in Marburg, Germany, consists of shipping containers fitted with the equipment necessary to make the company’s mRNA-based vaccine, save for the final step of putting doses into bottles, a…

Children aged between five and 11 will be offered two doses of the Pfizer vaccine in England

Pfizer/BioNTech jab to be offered to younger children as experts decide benefits outweigh risks Coronavirus – latest updates See all our coronavirus coverage Children aged between five and 11 in England will be offered a Covid vaccine, the UK government has confirmed, after similar announcements from Wales and Scotland this week. The move was recommended by the Joint Committee for Vaccination and Immunisation (JCVI), which decided that the vaccination programme should be extended to younger children after lengthy discussions on the benefits and risks. Continue reading…

BioNTech SE (NASDAQ: BNTX ), which developed the first widely approved COVID-19 shot together with Pfizer Inc (NYSE: PFE ), unveiled plans to establish manufacturing facilities in Africa to boost the availability of much-needed medicines on the continent. The manufacturing solution consists of one drug substance and one formulation module, allowing for mRNA vaccine production in bulk (mRNA manufacturing and formulation). Local partners will take over fill-and-finish. The first turnkey facility will … Full story available on Benzinga.com

"A Recurring Fountain Of Revenue": FDA Exec Admits Biden Planning Annual Shots, Including Toddlers Food and Drug Administration (FDA) Executive Officer Christopher Cole was caught on undercover camera by Project Veritas , where he revealed that his agency plans to announce that annual Covid-19 vaccinations will become official policy . As Project Veritas reports (emphasis ours): Cole is an Executive Officer heading up the agency’s Countermeasures Initiatives, which plays a critical role in ensuring that drugs, vaccines, and other measures to counter infectious diseases and viruses are safe. He made the revelations on a hidden camera to an undercover Project Veritas reporter. Cole indicates that annual COVID-19 shots isn’t probable -- but certain . When pushed on how he knows an annual shot will become policy, Cole states, “ Just from everything I’ve heard, they [FDA] are not going to not approve it .” Stop what you’re doing & watch this right now. “The drug companies, the food companies, they pay us millions of dollars a year” #ExposeFDA https://t.co/eyYmBlEfOj — Ashley St.

Image provided by Pexels This post contains sponsored advertising content. This content is for informational purposes only and is not intended to be investing advice. Oncolytics Biotech Inc. (NASDAQ: ONCY ) in January announced its partner in China — Adlai Nortye — has advanced the second dose level in a bridging clinical trial evaluating Oncolytics’ pelareorep in combination with paclitaxel therapy as a treatment for metastatic breast cancer. The news came after determination that the first dose level administered beginning in October showed no safety issues, and Oncolytics continues to complete parallel clinical trials of the same treatment in North America in collaboration with Pfizer Inc. (NYSE: PFE ) and Merck KGaA (OTCMKTS: MKKGY). The bridging trial will allow Adlai Nortye to include data from the North American metastatic breast cancer trials of the same combination treatment in future submissions to the National Medical Products Administration (NMPA), China’s regulatory equivalent of the Food and Drug Administration (FDA).

German vaccine maker BioNTech, which developed the first widely approved shot against COVID-19 together with Pfizer, unveiled plans Wednesday to establish manufacturing facilities in Africa that would

BioNTech SE said Wednesday it is developing turkey mRNA manufacturing facilities based on a container solution in an effort to promote scalable vaccine production in Africa. The company is expecting to deliver the first BioNTainer in the second half, comprising one drug substance and one formulation module. "Each module is built of six ISO sized containers (2.6m x 2.4m x 12m). This allows for mRNA vaccine production in bulk (mRNA manufacturing and formulation), while fill-and-finish will be taken over by local partners. Each BioNTainer is a clean room which BioNTech equips with state-of-the-art manufacturing solutions," the company said in a statement. Two modules will require 800 square meters of space and will have an initial capacity to produce up to 50 million doses of the COVID vaccine BioNTech developed with Pfizer Inc. . The company is expecting to ship BioNTainers to Rwanda, Senegal and potentially South Africa in close coordination with the respective country and the African Union.

Two elements could keep major revenue flowing.

Top US health group finds Pfizer and Moderna shots given to expecting mothers cut the rate of later coronavirus infection among their babies in half

Prime Minister Pham Minh Chinh has proposed Chairman and CEO of Pfizer Albert Bourla help accelerate the delivery of 22 million doses of its COVID-19 vaccine for children aged 5-11 in Vietnam in the coming days, with a goal of completing the contract in April or May at the latest.